NuVasive Stock Forecast, Price & News

NuVasive (NASDAQ:NUVA) Frequently Asked Questions

Is NuVasive a buy right now?

14 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for NuVasive in the last twelve months. There are currently 2 sell ratings, 5 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" NuVasive stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NUVA, but not buy additional shares or sell existing shares.
View analyst ratings for NuVasive or view top-rated stocks.

How has NuVasive's stock price been impacted by Coronavirus?

NuVasive's stock was trading at $49.41 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, NUVA stock has decreased by 2.7% and is now trading at $48.06.
View which stocks have been most impacted by COVID-19.

Are investors shorting NuVasive?

NuVasive saw a increase in short interest in the month of November. As of November 15th, there was short interest totaling 4,970,000 shares, an increase of 25.5% from the October 31st total of 3,960,000 shares. Based on an average daily trading volume, of 836,100 shares, the short-interest ratio is currently 5.9 days. Approximately 9.7% of the company's stock are sold short.
View NuVasive's Short Interest.

When is NuVasive's next earnings date?

NuVasive is scheduled to release its next quarterly earnings announcement on Thursday, February 24th 2022.
View our earnings forecast for NuVasive.

How were NuVasive's earnings last quarter?

NuVasive, Inc. (NASDAQ:NUVA) posted its quarterly earnings results on Tuesday, November, 9th. The medical device company reported $0.32 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.54 by $0.22. NuVasive had a positive trailing twelve-month return on equity of 11.40% and a negative net margin of 2.27%. During the same quarter in the prior year, the business posted $0.54 earnings per share.
View NuVasive's earnings history.

How will NuVasive's stock buyback program work?

NuVasive announced that its board has initiated a share repurchase plan on Tuesday, November 9th 2021, which authorizes the company to repurchase $100,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization authorizes the company to purchase up to 3.5% of its stock through open market purchases. Stock repurchase plans are generally a sign that the company's leadership believes its stock is undervalued.

What guidance has NuVasive issued on next quarter's earnings?

NuVasive issued an update on its FY 2021 earnings guidance on Tuesday, November, 30th. The company provided earnings per share (EPS) guidance of $1.730-$1.830 for the period, compared to the Thomson Reuters consensus EPS estimate of $2.230. The company issued revenue guidance of $1.13 billion-$1.14 billion, compared to the consensus revenue estimate of $1.19 billion.

What price target have analysts set for NUVA?

14 analysts have issued twelve-month price objectives for NuVasive's stock. Their forecasts range from $48.00 to $83.00. On average, they anticipate NuVasive's stock price to reach $66.92 in the next year. This suggests a possible upside of 39.2% from the stock's current price.
View analysts' price targets for NuVasive or view top-rated stocks among Wall Street analysts.

Who are NuVasive's key executives?

NuVasive's management team includes the following people:

• J. Christopher Barry, Chief Executive Officer & Director (LinkedIn Profile)
• Dale Wolf, Senior Vice President-Global Operations
• Matthew K. Harbaugh, Chief Financial Officer & Executive Vice President
• Kyle Malone, VP-Clinical, Medical & Regulatory Affairs
• Ryan Donahoe, Chief Technology Officer

What is Chris Barry's approval rating as NuVasive's CEO?

59 employees have rated NuVasive CEO Chris Barry on Glassdoor.com. Chris Barry has an approval rating of 88% among NuVasive's employees.

Who are some of NuVasive's key competitors?

Some companies that are related to NuVasive include Abbott Laboratories (ABT), Medtronic (MDT), Intuitive Surgical (ISRG), Stryker (SYK), Becton, Dickinson and (BDX), Edwards Lifesciences (EW), DexCom (DXCM), Boston Scientific (BSX), IDEXX Laboratories (IDXX), Baxter International (BAX), ResMed (RMD), STERIS (STE), Insulet (PODD), Hologic (HOLX) and Masimo (MASI).
View all of NUVA's competitors.

What other stocks do shareholders of NuVasive own?

Based on aggregate information from My MarketBeat watchlists, some companies that other NuVasive investors own include BioMarin Pharmaceutical (BMRN), Incyte (INCY), Puma Biotechnology (PBYI), Intel (INTC), Alibaba Group (BABA), (MDVN) (MDVN), Micron Technology (MU), Bank of America (BAC), Gilead Sciences (GILD) and Applied Materials (AMAT).

What is NuVasive's stock symbol?

NuVasive trades on the NASDAQ under the ticker symbol "NUVA."

Who are NuVasive's major shareholders?

NuVasive's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Thrivent Financial for Lutherans (3.73%), Paradice Investment Management LLC (2.66%), Dimensional Fund Advisors LP (2.58%), Geode Capital Management LLC (1.72%), Fisher Asset Management LLC (1.48%) and Stephens Investment Management Group LLC (1.41%). Company insiders that own NuVasive stock include James Christopher Barry, Lucas Vitale, Massimo Calafiore and Matthew Link.
View institutional ownership trends for NuVasive.

Which institutional investors are selling NuVasive stock?

NUVA stock was sold by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Two Sigma Advisers LP, Primecap Management Co. CA, Eagle Asset Management Inc., LPL Financial LLC, Gyon Technologies Capital Management LP, Rothschild & Co. Asset Management US Inc., and Neuberger Berman Group LLC. Company insiders that have sold NuVasive company stock in the last year include James Christopher Barry, Lucas Vitale, and Massimo Calafiore.
View insider buying and selling activity for NuVasive or view top insider-selling stocks.

Which institutional investors are buying NuVasive stock?

NUVA stock was acquired by a variety of institutional investors in the last quarter, including William Blair Investment Management LLC, Thrivent Financial for Lutherans, Paradice Investment Management LLC, Pura Vida Investments LLC, Balyasny Asset Management LLC, Polar Asset Management Partners Inc., Dimensional Fund Advisors LP, and Stephens Investment Management Group LLC.
View insider buying and selling activity for NuVasive or or view top insider-buying stocks.

How do I buy shares of NuVasive?

Shares of NUVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is NuVasive's stock price today?

One share of NUVA stock can currently be purchased for approximately $48.06.

How much money does NuVasive make?

NuVasive has a market capitalization of $2.49 billion and generates $1.05 billion in revenue each year. The medical device company earns $-37.15 million in net income (profit) each year or ($0.51) on an earnings per share basis.

How many employees does NuVasive have?

NuVasive employs 2,700 workers across the globe.

Does NuVasive have any subsidiaries?

The following companies are subsidiares of NuVasive: Biotronic NeuroNetwork, Ellipse Technologies, and SafePassage.

When was NuVasive founded?

NuVasive was founded in 1997.

What is NuVasive's official website?

The official website for NuVasive is www.nuvasive.com.

Where are NuVasive's headquarters?

NuVasive is headquartered at 7475 LUSK BOULEVARD, SAN DIEGO CA, 92121.

How can I contact NuVasive?

NuVasive's mailing address is 7475 LUSK BOULEVARD, SAN DIEGO CA, 92121. The medical device company can be reached via phone at (858) 909-1800, via email at [email protected], or via fax at 800-475-9134.